Stago will sell its products directly or through other distribution channels. However, Roche Diagnostics Japan will continue to distribute the Stago portfolio within the Japanese market under a separate agreement.

Both Roche and Stago are committed to respond to current and future needs of hemostasis customers. During a three-year transition period Stago and Roche have an agreement to ensure that all contractual obligations regarding Stago products that Roche has or will enter into can be fulfilled by Roche.

Bertrand Bonnot, COO of Stago, said, "We are convinced that, after almost 40 years of successful partnership, it is the right timing for both companies to follow independent paths. Nevertheless, both Stago and Roche are committed to work together to ensure a seamless transition in the coming years.”

Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. A biotech company with differentiated medicines in oncology, virology, inflammation, metabolism, and CNS, Roche is also a leader in in-vitro diagnostics (IVD), tissue-based cancer diagnostics, and a pioneer in diabetes management.

Stago is an IVD company, which develops and markets reagents and automated systems for the investigation of blood coagulation disorders. Stago is an industry leader in the science of hemostasis and thrombosis.

Related Links:
Roche
Diagnostica Stago